Albany Molecular Research (AMRI) Tops Q3 EPS by 4c

November 8, 2016 7:44 AM EST

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.17, $0.04 better than the analyst estimate of $0.13. Revenue for the quarter came in at $151.7 million versus the consensus estimate of $160.75 million.

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment